NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis $4.12 +0.27 (+7.01%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Aileron Therapeutics Stock (NASDAQ:ALRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aileron Therapeutics alerts:Sign Up Key Stats Today's Range$3.65▼$4.1250-Day Range$2.32▼$4.0852-Week Range$1.01▼$7.42Volume64,973 shsAverage Volume73,739 shsMarket Capitalization$89.05 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingStrong Buy Company OverviewAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Read More… I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Aileron Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreALRN MarketRank™: Aileron Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 259th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingAileron Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAileron Therapeutics has received no research coverage in the past 90 days.Read more about Aileron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aileron Therapeutics are expected to grow in the coming year, from ($1.41) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aileron Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.31% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aileron Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.31% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aileron Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly. News and Social Media4.0 / 5News Sentiment1.19 News SentimentAileron Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aileron Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for ALRN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.57% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by Institutions90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aileron Therapeutics' insider trading history. Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALRN Stock News HeadlinesAileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for RetinoblastomaOctober 31 at 7:30 AM | prnewswire.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Declines By 14.2%October 29 at 3:00 AM | americanbankingnews.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…October 31, 2024 | WealthPress (Ad)Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisOctober 12, 2024 | prnewswire.comAileron Therapeutics (NASDAQ:ALRN) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comAileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)September 23, 2024 | prnewswire.comAileron Therapeutics reports voting results from annual meetingAugust 24, 2024 | investing.comAileron Therapeutics to Present at the 8th Annual IPF SummitAugust 19, 2024 | prnewswire.comSee More Headlines ALRN Stock Analysis - Frequently Asked Questions How have ALRN shares performed this year? Aileron Therapeutics' stock was trading at $3.05 at the start of the year. Since then, ALRN stock has increased by 35.1% and is now trading at $4.12. View the best growth stocks for 2024 here. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.20. When did Aileron Therapeutics' stock split? Aileron Therapeutics's stock reverse split on the morning of Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aileron Therapeutics IPO? Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. Who are Aileron Therapeutics' major shareholders? Top institutional investors of Aileron Therapeutics include KG&L Capital Management LLC (0.06%). Insiders that own company stock include Of Texas/Texas Am I University and James Brian Windsor. View institutional ownership trends. How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN). Company Calendar Last Earnings8/14/2024Today10/31/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+371.5%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-30.81% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book2.86Miscellaneous Outstanding Shares21,615,000Free Float20,561,000Market Cap$87.11 million OptionableNot Optionable Beta2.35 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:ALRN) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.